Welcome to our dedicated page for CalciMedica SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
Bering Partners II and affiliates filed a Schedule 13D reporting beneficial ownership of 2,113,513 shares of CalciMedica common stock, representing 6.9% of the outstanding shares. The stake is held through Bering Partners II, L.P., a venture capital investment entity.
The position was built through shares received in CalciMedica’s merger with Graybug Vision, prior private placements, open-market purchases, an underwritten offering, and a June 25, 2026 private placement in which Bering II bought 1,450,267 units at $0.8033 per unit. Bering II also holds warrants, including a remaining warrant at an exercise price of $7.15 and rights to receive Series A and Series B warrants, all subject to ownership caps generally not exceeding 19.99%.
CalciMedica investors Eric Roberts and A. Rachel Leheny have increased their stakes and updated their ownership disclosures in an Amendment No. 4 to Schedule 13D. As of a total of 30,736,401 common shares outstanding on June 25, 2026, Roberts beneficially owns 1,965,916 shares, or 6.4% of the class, and Leheny beneficially owns 1,926,347 shares, or 6.3%.
The filing details numerous open-market purchases of CalciMedica common stock by both individuals during mid-2025, along with an option exercise by Roberts. It also notes that on June 25, 2026, Roberts and Leheny each acquired 186,729 Units at $0.8033 per Unit in a public offering, with each Unit consisting of one share and one pre-funded warrant, funded with their personal capital.
CalciMedica, Inc. reported that an investment fund affiliated with director and 10% owner Fred A. Middleton increased its stake. On June 25, 2026, Sanderling Venture Partners VI Co-Investment Fund, L.P. acquired 248,972 shares of common stock at $0.8033 per share. The shares were purchased directly from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board. Following this transaction, that fund holds 1,063,272 shares of CalciMedica common stock. Middleton also reports additional direct and indirect holdings, including 36,514 shares held directly and various positions through Sanderling and Golden Triangle entities, while disclaiming beneficial ownership beyond his pecuniary interest.
CalciMedica, Inc. Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of Common Stock on June 25, 2026 at an indicated price of $0.8033 per share. This brings his direct holdings to 186,025 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board of directors.
CalciMedica director Robert N. Wilson acquired 1,182,621 shares of Common Stock at $0.8033 per share. After this transaction, he directly holds 1,604,650 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent board committee and closed on June 25, 2026.
CalciMedica, Inc. director and chief business officer Eric W. Roberts reported a stock award of common shares. He acquired 186,729 shares of common stock at $0.8033 per share in a grant or award transaction. The securities were issued under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026, which was approved by an independent committee of the board of directors.
Following this grant, Roberts directly holds 366,435 common shares. He also has indirect holdings through several entities and retirement accounts, including 316,109 shares held by Valence Investments SPV VI, LLC, 356,989 shares held by Valence Investments SPV IV, LLC, and additional positions in IRA and Roth IRA accounts.
CalciMedica, Inc. director, chief executive officer and 10% owner Rachel A. Leheny reported acquiring 186,729 shares of common stock at $0.8033 per share. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026 with a closing date of June 25, 2026, which was approved by an independent committee of the board. Following this transaction, she directly holds 317,655 common shares. She is also reported as indirectly holding 316,109 shares through Valence Investments SPV VI, LLC, 66,228 through Valence Investments SPV V, LLC, 356,989 through Valence Investments SPV IV, LLC, 3,500 through the Scheibler-Leheny Family Living Trust, and 1,000 through her spouse, while disclaiming beneficial ownership of the Valence entities’ holdings except to the extent of her pecuniary interest.
CalciMedica, Inc. Amendment to a Schedule 13G/A updates beneficial ownership disclosures for Avenue-related reporting persons following a First Amendment to Loan Documents effective June 23, 2026. The amendment describes a 4.99% ownership Blocker that prevents conversion of loans into common stock beyond that threshold.
The filing reports that the lenders' position reflects 4,641,163 shares and 4.99% of the issuer on a fully diluted basis calculated from 30,736,401 shares as of June 24, 2026. It discloses an aggregate outstanding principal of $10,000,000, conversion rights for up to $3,000,000 at $1.00 per share, an original loan capacity of $32 million, and that the Blocker may be increased to 19.99% upon at least 61 days' notice.
CalciMedica, Inc. entered a securities purchase agreement for a private placement of 18,673,429 units, providing approximately $15 million in upfront gross proceeds and up to about $49 million in total potential gross proceeds including Series A and Series B warrant exercises.
Each unit includes common stock or a pre-funded warrant plus rights to Series A and B warrants, with exercise prices of $0.8033 and $1.00 per share, respectively. The company plans to use the funds to advance a pulmonary hypertension program, including a Phase 1b Auxora proof-of-concept study in PAH and IND-enabling work for oral candidate CM5480.
The company estimates that net proceeds, together with existing cash, will fund operations into the second half of 2027. CalciMedica also reported that the FDA reviewed a protocol amendment and interim safety data for the Phase 2 KOURAGE trial of Auxora in acute kidney injury and provided no comments, allowing dosing in the study to continue.
CalciMedica, Inc. amended its loan and warrant arrangements with Avenue funds, extending debt maturity and adding equity-linked features. The company’s $10,000,000 loan now has an interest-only period through September 30, 2027 and a new maturity date of September 1, 2029, in exchange for a $200,000 increase in the final payment fee.
The lender’s conversion right was expanded to allow conversion of up to $3,000,000 of loan principal into common stock or pre-funded warrants at a $1.00 stock purchase price, subject to volume and price conditions and beneficial ownership limits. CalciMedica also reduced the exercise price of an existing warrant on 641,163 shares to $1.00 and issued a new warrant for 1,000,000 shares at $1.00, both with a beneficial ownership cap not to exceed 19.99%. The new warrant is exercisable until June 23, 2031 and, along with the conversion and related securities, was issued in a private transaction relying on a Section 4(a)(2) exemption.